2000年9月—2003年7月 医学硕士 大连医科大学 1995年9月—2000年7月 医学学士 大连医科大学

2012年12月—至今 副教授 大连医科大学 2005年8月—2012年11月 讲师 大连医科大学 2003年7月—2005年7月 助教 大连医科大学

1.国家自然科学基金项目，miR-497介导局灶节段性肾小球硬化（FSGS)足细胞损伤的机制研究（81600527）,2017/01-2019/12，排名1 2..973科技计划项目子课题，常见肾小球疾病发机制及其早期诊断(2012CB517600)，2012/01-2016/12,排名 2 3.国家自然科学基金青年基金，基于RNA aptamer主动靶向于肿瘤干细胞的纳米金载药系统的构建和研究（81202484）,2012/01-2015/12，排名 2

[1] Zhang X ,Guo G ,Wang G,Zhao J,Wang B,Yu X ,Ding Y,Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma，Molecular Medicine Reports (IF=1.559)，2015,12(6)：8021-8031.(通讯作者) [2] Zhao H, Ding Y,Tie B,Sun ZF,Jiang JY,Zhao J,Lin X,Cui S.miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC，International Journal of Oncology(IF=3.018),2013,43(3)：839-849.(并列第一作者) [3] Ding YF,Wang G.,Zhao J, Wu X,Cui M,Li T, Li Y, Cui S.The role of miR-200c in ovarian cancer patients with paclitaxel resistance. International Journal of Gynecological Cancer.(IF=2.116),2016,26(suppl 3):672-672 [4] DingY, Zhang X, Cui S.Role of miR-206 in cisplatin resistance of ovarian serous carcinoma.International Journal of Gynecological Cancer (IF=1.958) 2014, 24 (9) : 88-88 [5] Zhao HN,Yu XT,Ding YF,Zhao JY,Wang G ,Wu X,Jiang JY ,Peng C ,Guo GZ, Cui SY.MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2, ONCOTARGET (IF = 5), 7( 33): 53254-53268 [6] Wang YT, Wang CY , Zhao J,Ding YF, Li L .A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailabilityJOURNAL OF COLLOID AND INTERFACE SCIENCE(IF=3.782)，485 : 91-98 [7] Xu YW ,Wang CY ,Ding YF , Wang YT,Liu KX ,Tian Y ,Gao M, Li Z ,Zhang JB,Li, L .Nanoparticles with Optimal Ratiometric Co-Delivery of Docetaxel with Gambogic Acid for Treatment of Multidrug-Resistant Breast Cancer. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY(IF=3.929),201612(9) :1774-1781 [8] Zhao H,Liu S,Wang G,Wu X,Ding Y,Guo G,Jiang J ,Cui S .Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer, Oncology Reports(IF=2.6),2014,33(2)：591-598. [9] Yu X,Zhang X ,Bi T，Ding Y, Zhao J,Wang C,Jia T,Han D,Guo G，Wang B，Jiang J,Cui S，MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma，Tumor Biology(IF=2.5),2013,34（6）：3501-3508. [10] Zhao JY,Liu CQ,Zhao H,Ding YF,Bi T,Wang B,Lin XC,Guo G, Cui SY. Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: Applications in clinical and basic research，Methods(IF=3.7)，2012,58(2)：156-163